- WKN: 656990
- ISIN: DE0006569908
- Land: Deutschland
Nachricht vom 01.10.2021 | 19:16
MLP SE: MLP SE anticipates to significantly exceed its own EBIT forecast for 2021, as well as to record significantly higher Q3 EBIT for 2021 than in the previous year
MLP SE / Key word(s): Forecast/Change in Forecast
In the third quarter of 2021, MLP SE recorded significantly higher performance-based compensation than previously projected. With positive overall performance in its consulting fields, the MLP Group therefore anticipates to significantly exceed its current EBIT forecast for 2021 (upper end of the corridor from EUR 55 to 61 million), as well as to record significantly higher EBIT for Q3 2021 than in the same period of the previous year (Q3 2020: EUR 8.1 million).
Performance-based compensation is accrued for the positive performance of investment concepts in wealth management and is largely recognised in income. The sales revenue effect of the performance-based compensation in the third quarter of 2021 is around EUR 17 million. In the same period of the previous year (Q3 2020), MLP recorded a sales revenue effect from performance-based compensation of EUR 8.0 million.
Based on the successful business development recorded in the first half of 2021, MLP has already specified its EBIT forecast for the financial year 2021 on August 12, 2021, stating that it would probably reach the upper end of the announced corridor of EUR 55 to 61 million.
MLP will report the full financial figures for the third quarter of 2021 on November 11 as scheduled.
Performance-based compensation and EBIT represent alternative KPIs, which are described in further detail at:
|Alte Heerstraße 40|
|Listed:||Regulated Market in Frankfurt (Prime Standard), Stuttgart; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Tradegate Exchange|
|EQS News ID:||1237697|
|End of Announcement||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
29. November 11:15 Teamviewer: 80 Prozent im Minus – und es kann noch schlimmer kommen
29. November 11:41 Evotec: "Profiteur der Megatrends im Biotech-Bereich"
29. November 12:00 Bitcoin: Der Rebound läuft – Trading-Chance für Mutige
29. November 12:45 Nel nach wilder Woche: So machen Trader jetzt weiter
29. November 12:49 Standard Lithium: 1.150 Prozent sind nicht genug – Nachfolger steht ...
Original-Research: Gold Mountain Mining Corp. (von hanseatic stock publishing UG (haftungsbeschränkt)): Gold Mountain Mining Corp.
29. November 2021